Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular carcinoma

References

• Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001;41:775–87.
   PubMed Web of Science ®Google Scholar
• Fredholm B, Ijzerman A, Jacobson K, et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 2001;53:527–52.
   PubMed Web of Science ®Google Scholar
• Sadana R, Dessauer C. Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neurosignals 2009;17:5–22.
   PubMedGoogle Scholar
• Tang X, Wang Y, Li D, et al. Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets. Acta Pharmacologica Sinica 2012;33:363–71.
   PubMed Web of Science ®Google Scholar
• Pierce K, Premont R, Lefkowitz R. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002;3:639–50.
   PubMed Web of Science ®Google Scholar
• Jacobson K, In adenosine receptors in health and disease. Berlin Heidelberg: Springer; 2009. 1–24 p.
   Google Scholar
• Chen J, Eltzschig H, Fredholm B. Adenosine receptors as drug targets-what are the challenges? Nat Rev Drug Discov 2013;12:265–86.
   PubMed Web of Science ®Google Scholar
• Müller C, Jacobson K. Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Et Biophys Acta 2011;1808:1290–308.
   PubMed Web of Science ®Google Scholar
• Mustafa S, Morrison R, Teng B, Pelleg A. Adenosine receptors and the heart: role in regulation of coronary blood flow and cardiac electrophysiology. Handb Exp Pharmacol 2009;161–88.
   PubMedGoogle Scholar
• Thomas G, Thompson R, Miyamoto M, et al. The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A (2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63–72.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Liang B, Jacobson K. Pharmacological and therapeutic effects of A3 adenosine receptor (A3AR) agonists. Drug Discovery Today 2012;17:359–66.
   PubMed Web of Science ®Google Scholar
• Bar-Yehuda S, Stemmer S, Madi L, et al. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. Int J Oncol 2008;33:287–95.
   PubMed Web of Science ®Google Scholar
• Ciancetta A, Jacobson K. Structural probing and molecular modeling of the A3 adenosine receptor: a focus on agonist binding. Molecules 2017;22:449.
   Web of Science ®Google Scholar
• Tosh D, Deflorian F, Phan K, et al. Structure-guided design of A3 adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem 2012;55:4847–60.
   PubMed Web of Science ®Google Scholar
• Deganutti G, Cuzzolin A, Ciancetta A, Moro S. Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: a prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000. Bioorg Med Chem 2015;23:4065–71.
   PubMed Web of Science ®Google Scholar
• (A) Yaziji V, Rodríguez D, Gutiérrez-de-Terán H, et al. Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem 2011;54:457–71. (B) Wei J, Li H, Qu W, Gao Q. Molecular docking study of A(3) adenosine receptor antagonists and pharmacophore-based drug design. Neurochem Int 2009;55:637–42.
   PubMed Web of Science ®Google Scholar
• Forst T, Pfützner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother 2012;13:101–10.
   PubMed Web of Science ®Google Scholar
• Mourad S, El-Kimary E, Hamdy D, Barary MA. Stability-indicating HPLC-DAD method for the determination of linagliptin in tablet dosage form: application to degradation kinetics. J Chromatogr Sci 2016;54:1560–6.
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J immunol Methods 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• Grove S, Faller R, Soleim K, Dannevig B. Absolute quantitation of RNA by a competitive real-time RT-PCR method using piscine nodavirus as a model. J Virol Methods 2006;132:104–12.
   PubMed Web of Science ®Google Scholar
• Livak K, Schmittgen T. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method)). Methods 2001;25:402–8.
   PubMed Web of Science ®Google Scholar
• (A) Katritch V, Kufareva I, Abagyan R. Structure based prediction of subtype-selectivity for adenosine receptor antagonists. Neuropharmacology 2011;60:108–15. (B) Floris M, Sabbadin D, Medda R, et al. Adenosiland: walking through adenosine receptors landscape. Eur J Med Chem 2012;58:248–57.
   PubMed Web of Science ®Google Scholar
• (A) Ahmed M, Kopel L, Halaweish F. Structural optimization and biological screening of a steroidal scaffold possessing cucurbitacin‐like functionalities as B‐raf inhibitors. Chem Med Chem 2014;9:1361–7. (B) Alsayari A, Kopel L, Ahmed M, et al. Design, synthesis, and biological evaluation of steroidal analogs as estrogenic/anti-estrogenic agents. Steroids 2017;118:32–40. (C) Hawkins P, Skillman A, Warren G, et al. Conformer generation with OMEGA: algorithm and validation using high quality structures from the protein databank and cambridge structural database. J Chem Inf Model 2010;50:572–84. (D) Mcgann M. FRED pose prediction and virtual screening accuracy. J Chem Inf Model 2011;5:578–96.
   Web of Science ®Google Scholar
• Zhang H, Sun L, Zou L, et al. Identification, characterization and HPLC quantification of process-related impurities in Trelagliptin succinate bulk drug: six identified as new compounds. J Pharm Biomed Anal 2016;128:18–27.
   PubMed Web of Science ®Google Scholar
• Deng S, Li Z, Jiang J, et al. Determination of related substances in trelagliptin succinate by RP-HPLC and identification of impurities from acid degradation by LC-MS/MS. Chin J New Drugs 2016;25:226–31.
   Google Scholar
• Zhou Y, Zhou W, Sun L, et al. Characterization of process-related impurities including forced degradation products of alogliptin benzoate and the development of the corresponding reversed-phase high-performance liquid chromatography method. J Sep Sci 2014;7:1248–55.
   Web of Science ®Google Scholar
• Zaghary W, Mowaka S, Hassan M, Ayoub B. Suitability of various chromatographic and spectroscopic techniques for analysis and kinetic degradation study of trelagliptin. Sci Rep 2017;7:17255.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Ardon E, et al. Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist. Anticancer Res 2003;23:2077–83.
   PubMed Web of Science ®Google Scholar
• Madi L, Bar-Yehuda S, Barer F, et al. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 2003;278:42121–30.
   PubMed Web of Science ®Google Scholar
• Ohana G, Bar-Yehuda S, Arich A, et al. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer 2003;89:552–8.
   PubMed Web of Science ®Google Scholar
• Aghaei M, Panjehpour M, Karami-Tehrani F, Salami S. Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. J Cancer Res Clin Oncol 2011;137:1511–23.
   PubMed Web of Science ®Google Scholar
• Xiao Z, Yao Y, Long Y, Devreotes P. Desensitization of G-protein-coupled Receptors Agonist-Induced phosphorylation of the chemiattractant receptorcAR1 lowers its intrinsic affinity for cAMP. J Biol Chem 1999;274:1440–8.
   PubMed Web of Science ®Google Scholar
• Ferguson S. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001;53:1–24.
   PubMed Web of Science ®Google Scholar
• Trincavelli M, Tuscano D, Cecchetti P, et al. Agonist-induced internalization and recycling of the human A(3) adenosine receptors: role in receptor desensitization and resensitization. J Neurochem 2000;75:1493–501.
   PubMed Web of Science ®Google Scholar